WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"
SHANGHAI and LONDON, December 6, 2018 – Wuxi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has won the SCRIP Award in the category of "Best Company in an Emerging Market". This award recognizes the rapid growth, significant accomplishments, and growing global influence achieved by WuXi Biologics in 2018. WuXi Biologics was presented with the award at the 14th Annual SCRIP Awards ceremony held in London on November 28, 2018.
The SCRIP Awards are one of the industry's most prestigious awards to applaud the essential roles that the pharmaceutical, biotech and other allied industries play in improving healthcare. Its categories span the entire range of industry activities, celebrating the excellent work done by individuals, teams and companies.
"We are excited and honored to be selected as the 'Best Company in an Emerging Market' at the prestigious SCRIP Awards," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "This award should be given to our world-class team, one of the largest globally with approximately 4,000 employees, and more than 200 clients and partners around the world. All their efforts, ingenuity and dedication have been making a real difference in the quest to discover, develop and manufacture innovative biologics for global patients. WuXi Biologics will continue to focus on expanding our capabilities and capacities to transform and accelerate biologics discovery, development and manufacturing, further empowering our partners and benefiting patients worldwide."
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
Media Contact:
WuXi Biologics
Jia Li
li_jia0102@wuxiapptec.com